Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurothera LabsFRA:C0A +0.34%32 Buyback Yield % is 0.00 as of Aug. 12, 2026. GuruFocus rates FRA:C0A with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 272 Drug Manufacturers companies, Neurothera Labs ranks worse than 367646.69% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Neurothera Labs's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:C0A vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Neurothera Labs's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurothera Labs Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Neurothera Labs's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurothera Labs (FRA:C0A) has a Buyback Yield % of 0.00 as of Aug. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neurothera Labs and its competitors. According to the industry distribution chart, Neurothera Labs ranks #999999 out of 272 companies in the Drug Manufacturers industry.
Is Neurothera Labs' Buyback Yield % too high?
Neurothera Labs' current Buyback Yield % is 0.00. Based on the distribution chart, Neurothera Labs ranks #999999 out of 272 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurothera Labs has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Neurothera Labs ranks #999999 out of 272 companies for Buyback Yield %. This places Neurothera Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neurothera Labs and its competitors. Neurothera Labs's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (FRA:C0A) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Neurothera Labs' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Neurothera Labs (FRA:C0A), the current Buyback Yield % is 0.00 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score
Get the complete analysis for FRA:C0A
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C0A has been successfully added to your 
